Introduction {#s1}
============

Alzheimer disease (AD) is a complex and heterogeneous disorder strongly affecting the cognitive functions and the memory of seniors.

Many risk factors were proposed to be significant contributors for the AD onset such as senescence, autophagy defects, genetic factors \[i.e., ApolipoproteinaE-allele4 (APOE4), Triggering receptor expressed on myeloid cells 2 (Trem2)\], microbiota alterations, lifestyle choices, cardiovascular and traumatic brain injury, as well as environmental factors (level of education, hypertension, obesity, diabetes, smoking, hearing loss, depression, physical inactivity, social isolation) ([@B128]). It is now well accepted that important cellular pathways are compromised in AD. Together with intraneuronal neurofibrillary tangles (NFT) made of hyperphosphorylated tau protein and the extraneuronal senile plaques (SP) made of beta-amyloid (Aβ) peptides, synaptic failure, vascular damage, increased oxidative stress, neuronal and axonal injury, microglia-regulated neuroinflammation, and mitochondrial dysfunction are hallmarks of the disease ([**Figure 1**](#f1){ref-type="fig"}).

![The hallmarks that characterized AD are reported in the left side of the figure. On the right side, the mitochondria-related functions that are seriously compromised in AD are on focus.](fphar-10-00902-g001){#f1}

Along the past years, Aβ peptides have been considered one of the most promising therapeutic targets for AD. However, many clinical studies based on the Aβ cascade hypothesis failed, and the idea that Aβ pathology is not anymore the leading primary cause of AD has risen ([@B152]). Instead, nowadays the belief that AD is a multi-factorial disease is growing steadily, and mitochondrial dysfunction is one of the factors that may actively contribute to the disease onset and progression ([@B98]; [@B236]). Despite that, a logical temporal order of the events in AD, as well as a valid and effective therapy, is still missing. However, our society urgently requires medical interventions to counteract this deleterious disease because of the severe negative impact on the quality of lives of the afflicted patients as well as on the health system as a whole due to a rapidly aging population.

This review focuses on the description of the role of mitochondrial dysfunction and the status of mitochondrial therapy in AD. The main question addressed here is: could the mitochondrial organelle be a valid pharmacologic target to prevent or delay the AD onset or to block the AD progression?

Mitochondria {#s2}
============

The mitochondrion is a cellular organelle with a characteristic and unique structure formed by two membranes, respectively called outer mitochondrial membrane (OMM) and inner mitochondrial membrane (IMM) that surround the matrix. Mitochondria are defined as the powerhouse of the cell because every cell in the human body relies on the energy provided by these organelles to sustain their vital functions. Mitochondrial energy production via the so-called process of oxidative phosphorylation takes place at the IMM through the activity of respiratory chain complexes (RCC), generating an inner membrane potential (mtΔΨ) that is used by the ATP-synthase enzyme complex to synthesize adenosine triphosphate (ATP). This process depends on the supply of reducing equivalents by the end-oxidation of nutrients *via* the Krebs cycle or β-oxidation in the mitochondrial matrix compartment ([@B220]). Mitochondria contain their own DNA (mtDNA) located in the matrix that encodes mainly 13 protein subunits of the RCC. All other mitochondrial protein components are encoded in the nuclear DNA (nuDNA) and are imported into the organelle after the translation at cytosolic ribosomes. Hence, the maintenance of an entire and functional mitochondrial proteome requires a fine-tuned and well-coordinated sequence of many reactions and a close integration of organellar and cellular biogenesis processes ([@B171]).

Neurons are strictly dependent on the presence of mitochondria in particular at the synapses where these organelles produce ATP and buffer Ca^2+^-ion concentration, both fundamental processes for the implementation of neurotransmission and generation of membrane potential along the axon ([@B123]; [@B238]; [@B79]). This justifies the high amount of mitochondria at the synaptic area, higher than any other part of the neurons. Linked to that, a correct and efficient transport of neuronal mitochondria at the synaptic terminals is fundamental for their correct function. Both non-synaptic and synaptic mitochondria are usually synthesized in the neuronal soma and then transported in the other area of the neurons where they are required. The transport of mitochondria along the axons is guaranteed *via* microtubules and requires motor proteins such as kinesin, dynein, as well as the OMM protein Mitochondrial Rho GTPase (Miro). Axonal transport of mitochondria is also influenced by the metabolic demand and the Ca^2+^ status at the synaptic level ([@B259]; [@B82]; [@B197]; [@B212]).

The enzymatic activity of the mitochondrial RCC results essentially in two "side effects." First, the generation of the mtΔΨ along the IMM is essential also for the execution of mitochondrial import of nuclear-encoded proteins and overall it is a parameter that reflects the health status of mitochondria and cells ([@B209]). Second, a leakage of electrons from the RCC contributes significantly to the formation of reactive oxygen species (ROS). Therefore, ROS are considered a typical by-product of bioenergetic pathways ([@B177]). However, under normal physiological conditions, ROS production is well balanced by the presence of adequate antioxidant systems, and the damage to the diverse cellular constituents is contained. However, during aging, as well as during several pathological conditions, in particular in neurodegenerative diseases, this equilibrium becomes unbalanced. Increased ROS concentrations result in molecular damage at the site where they are produced or, through diffusion, in surrounding areas, leading to the generation of the so-called oxidative stress condition. ROS targets essentially comprise all cellular macromolecules, ranging from proteins, lipids, carbohydrates, up to nucleic acids ([@B35]). The hippocampus region, the cortex, and more generally the brain are particularly vulnerable to oxidative stress because of their high consumption of oxygen and dependence on mitochondrial energy production. This susceptibility is increased by low levels of antioxidant defenses and a high content of polyunsaturated fats, which are especially vulnerable to oxidative alterations ([@B36]).

Mitochondria form a dynamic tubular network extended throughout the cytosol, a behavior that is often misrepresented by the cell biology textbooks. Two crucial processes, fusion and fission, regulate the entire morphology and structure of this mitochondrial network ([@B149]). During the fission reaction, a part of the mitochondrial tubule is divided into fragments, a process that is regulated by a member of the dynamin family, Dynamin-1-like protein (Drp1), together with the OMM fission factors Mitochondrial fission 1 protein (Fis1) and Mitochondrial dynamics protein MID49 \[Mitochondrial elongation factor 2 (MIEF2)\]. Fusion, where two or more pieces of mitochondria are fused together to one structure, happens through joint activity of the proteins Dynamin-like 120 kDa protein \[or Optic atrophy protein 1 (OPA1)\] and Mitofusin 1 and 2 (Mfn1 and Mfn2). Fusion/fission processes together with the precursor proteins import and internal proteins translation are part of the mitochondrial biogenesis in which the cells increase their mitochondrial mass ([@B201]). A master regulator of mitochondrial biogenesis is Peroxisome-proliferator-activated receptor γ coactivator-1α (PGC-1α) ([@B204]) that activates a series of transcriptional factors, including the Mitochondrial transcription factor A (TFAM), which regulates transcription and replication of mtDNA ([@B104]), and Nuclear respiratory factor 1 (NFR-1) and 2 (NFR-2), which control the mitochondrial protein-encoded nuclear genes ([@B204]).

The buffer of intracellular Ca^2+^ is mediated mainly by the cooperation between endoplasmic reticulum (ER) and mitochondria through the formation of contact sites ([@B117]) that permit the Ca^2+^ uptake from the cytosol and the exchange of the ion between the two organelles ([@B190]). Ca^2+^ regulates important mitochondrial metabolic enzymes ([@B145]). The mitochondria contain two types of Ca^2+^ channels: the Mitochondria calcium uniporter (MCU) with high selectivity for this ion and localized in the IMM ([@B43]) and the Voltage-dependent anion channel (VDAC) localized in the OMM that regulates the release of the Ca^2+^ from the mitochondria ([@B117]). Furthermore, VDAC cooperates with the adenine nucleotide transporter in the IMM and the cyclophin D (CypD) in the matrix on the formation of the mitochondrial permeability transition pore (mPTP) ([@B13]). An mPTP opening leads to activation of apoptosis and then cell death ([@B85]). As already mentioned above, at the synaptic level, mitochondria regulate the amount of Ca^2+^ fundamental for neurotransmission and in general for the exertion of synaptic functions ([@B252]; [@B15]).

Mitochondrial functions and eventually cellular homeostasis are guaranteed by a dedicated mitochondrial quality control system (mtQCS). The mtQCS comprises a multitude of different biochemical mechanisms that act at different levels, affecting individual polypeptides as well as the whole organelle. While the folding state and activities of mitochondrial proteins are controlled by endogenous chaperones and proteases ([@B241]), damaged mitochondria may be removed by a selective autophagy pathway, termed mitophagy ([@B261]). The primary regulator of the mitophagy is a specialized signaling system consisting of the protein PTEN-induced kinase 1 (Pink1) and the ubiquitin ligase Parkin that is activated after the loss of mtΔΨ ([@B194]). An accumulation of Pink1 at the OMM of damaged mitochondria is thought to recruit Parkin that leads to a labeling of the mitochondria for the subsequent mitophagy process. This is followed by the formation of an autophagosomal membrane engulfing the mitochondria followed by its fusion with the lysosomes where ultimately the digestion of the mitochondrial material takes place.

Mitochondrial dysfunction in AD {#s3}
===============================

In AD brain, the alteration of energetic pathways, also linked to the reduction of glucose consumption, is a well-established feature of the disease ([@B81]). The glucose uptake in the brain is usually measured with the positron emission tomography (PET) tracer 18-fluorodeoxyglucose (fDG). In subjects with AD, PET studies have consistently demonstrated a low rate of glucose metabolism (between 20% and 30% lower than healthy individuals) in brain regions involved in processing memory (e.g., the hippocampus, posterior cingulate, temporal, and parietal lobes) ([@B105]). Furthermore, it was proposed that the metabolic changes appeared earlier than the onset of the histopathological markers and symptoms ([@B81]). Although the real cause is still unclear, the defective metabolism that characterizes AD could be easily linked to mitochondrial dysfunction.

Since its formulation in 1992 ([@B91]), the "amyloid cascade hypothesis" has dominated the AD field in the past 30 years. This hypothesis was based on two clear evidences: Aβ peptides constitute the extraneuronal senile plaques and mutation of Aβ peptides precursor, amyloid-β precursor protein (APP), leads to an early onset of AD. However, due to the fails in all Phase III clinical trials in human AD, this hypothesis has substantially lost ground and needed to be strongly revised or integrated with other hypotheses ([@B106]). In 2004, a new hypothesis was proposed to explain the onset of sporadic AD. The hypothesis, called "mitochondrial cascade hypothesis," described that each human genetic heritage influences mitochondrial functions with a primary repercussion on the onset of AD pathology. In other words, according to this hypothesis, the mitochondrial dysfunction is the primary process to trigger all the cascade of events that lead to sporadic late-onset AD ([@B226]; [@B225]).

Despite the fact that the validity of the mitochondrial cascade hypothesis has yet to be demonstrated in different AD models as well as human patients, the following mitochondrial functions were found severely compromised in the AD context ([@B92]): mitochondrial morphology ([@B101]) and number ([@B94]), oxidative phosphorylation, mtΔΨ, Ca^2+^ buffering, ROS production ([@B20]), mtDNA oxidation and mutation ([@B245]), mitochondrial-ER contact sites ([@B6]), mitochondrial biogenesis, mitochondrial transport along the neuronal axon ([@B23]), and mitophagy ([**Figure 1**](#f1){ref-type="fig"}). In a neuronal context, any of these dysfunctional processes could lead to synaptic deficits and critical consequences not only for single neurons but also for a more complex structure like the brain ([@B22]).

In AD brains, the activities of the enzymes involved in mitochondrial energy production, such as complex IV cytochrome c oxidase (COX), pyruvate dehydrogenase complex, mitochondrial isocitrate dehydrogenase, α-ketoglutarate dehydrogenase (αKGDH), and ATP synthase complex were found decreased, while the succinate dehydrogenase (complex II) and malate dehydrogenase activities were increased ([@B144]; [@B25]; [@B81]; [@B255]). This definitely compromises the maintenance of the mtΔΨ and eventually of the mitochondrial ATP production ([@B12]).

In line with that, the imbalance between ROS production and antioxidant power was observed in AD brains, cerebrospinal fluid (CSF), and blood ([@B78]). Since the 1990s, the ROS-induced oxidative stress has received considerable attention as one of the main factors contributing to the AD pathogenesis ([@B141]). Already the mild cognitive impairment (MCI), an early stage in the AD chronology, is characterized by the significant increase of oxidative stress markers, such as lipid peroxidation and protein oxidation products, and the decrease of antioxidants in the brain and peripheral compartments ([@B174]; [@B188]; [@B21]).

The analysis of the samples from different AD experimental models and AD patients showed a strong link between the oxidative stress and mitochondrial dysfunction. In the transgenic mice over-expressing human APP (Tg mAPP mice), an early and progressive accumulation of Aβ peptide in synaptic mitochondria led to a mitochondrial synaptic dysfunction such as damaged mitochondrial respiratory activity, increased mPTP and oxidative stress, and impaired mitochondrial axonal transport ([@B56]). Data from the 3xTg-AD mice showed that the compromised mitochondria bioenergetics together with elevated oxidative stress levels are early phenomena appearing before the development of observable Aβ plaques ([@B92]; [@B258]). Oxidation of one of the mitochondrial enzymes involved in the oxidative phosphorylation, ATP synthase, was found in isolated lymphocytes from AD peripheral blood as well as in MCI and AD brains ([@B223]; [@B183]; [@B234]). This may explain the compromised activity of the ATP synthase and the reduction of ATP levels in AD. Another paper showed a correlation between the reduction of the mitochondrial enzyme Aconitase (ACO2) activity and the plasma antioxidant levels in peripheral lymphocytes from MCI and AD patients proving again the strong association between the oxidative stress and the mitochondrial dysfunction in AD ([@B138]). Interestingly, the new and innovative technology for AD modeling obtained with the human induced pluripotent stem cells (iPSCs) directly from AD patients demonstrated further that AD-relevant mitochondrial aberrations, including oxidative stress, have a causative role in the developments of the disease. Indeed, neurons and astrocytes from AD-iPSCs presented increased ROS production and RCC levels and enhanced susceptibility to the stressors ([@B157]; [@B158]; [@B16]).

The mitochondrial dynamics such as fusion and fission processes were found unbalanced in AD, potentially leading to i) compromised distribution and morphology of mitochondria in the neurons ([@B94]) and ii) fragmented mitochondria observed in fibroblasts and brains from AD patients ([@B248]; [@B250]). The mitochondrial fusion and fission proteins were differentially expressed in AD hippocampus with an increase of the mitochondrial fission protein Fis1 alongside with a significant downregulation of Drp1 and fusion proteins Mfn1, Mfn2, and OPA1 ([@B250]). Similar results were found in a AD cybrids model, together with bleb like- and shorter mitochondria compared to control samples ([@B77]). Furthermore, increased phosphorylation at Ser 616 site and S-nitrosylation of Drp1, which both facilitate the mitochondrial fission ([@B228]; [@B32]), were higher in a AD brains compared to control ([@B250]). Beside that, the protein Drp1 was seen interacting with Aβ and phosphorylated tau in brain homogenates from AD patients ([@B135]; [@B137]). A recent study performed in samples from AD and healthy control subjects showed the significant association between a specific polymorphism in *MFN2* gene and AD suggesting that genetic polymorphism of fusion process regulation might be involved in the AD pathogenesis ([@B112]). In addition, mfn2 protein act as a tether between mitochondria and ER membranes ([@B42]). In this regard, mfn2 influences the Presenilin 2 (PS2), whose mutation is linked to the familial AD (FAD), in the modulation of the mitochondria-ER contact sites ([@B73]).

Several experimental AD models linked to APP overexpression or Aβ peptides treatments are characterized as well by mitochondrial fragmentation and abnormal mitochondrial distribution along the neurons due to an alteration of mitochondrial fusion and fission proteins levels ([@B249]; [@B56]; [@B264]; [@B23]; [@B246]). All these results lead to two critical remarks: i) the altered balance between fusion and fission that interferes with mitochondrial transport contributes actively to the AD pathogenesis and ii) the mitochondrial dynamics impairment could be a new therapeutic target in AD.

Another key mitochondrial function, the mitochondrial biogenesis, was impaired in AD. The significant reduction of the number of mitochondria in AD human hippocampus and in cell culture models already suggests that the mitochondrial biogenesis is compromised ([@B94]; [@B249]). Furthermore, the level of protein regulating the mitochondrial biogenesis such as PGC-1α, NRF1 and 2, and TFAM was significantly reduced in human AD hippocampus and cellular models overexpressing APP Swedish mutation ([@B176]; [@B211]). In the AD mouse model harboring mutant human transgenes of APP and Presenilin-1 (PS1), the mitochondrial biogenesis markers were found again declined in particular in the hippocampus region, and the use of melatonin brought beneficial effects ([@B216]).

Interestingly, on one side, mitophagy was able to reverse the memory impairment, to prevent the cognitive deterioration and the Aβ peptide/tau pathology in several AD models ([@B71]). However, on the other side, mitophagy was also strongly affected in AD, leading to the accumulation of damaged mitochondria and consequently to dysfunctional neurons. One cause may be the impairment of the fusion between the autophagosome and lysosomes. This was observed in cultured cells overexpressing mutant APP, in AD mouse models, and also in neurons from AD patients' brain ([@B18]; [@B122]; [@B37]). In AD brains, the somatic mutations found in mtDNA are higher than in healthy brains, potentially triggering other neuropathological consequences such as the increased ROS production in neurons and the promotion of amyloidogenic processing of APP ([@B125]).

The two major and typical histopathological markers of AD, Aβ peptide and tau, harmfully accumulate in or interact non-specifically with mitochondria ([@B65]). Aβ peptide and abnormal tau negatively affect axonal transport and consequently the transport of mitochondria along the axon from the neuronal soma to the synapses. AD mouse models, overexpressing Aβ peptides, have damaged mitochondria usually characterized by impaired axonal transport of mitochondria, a reduced mtΔΨ, and inhibited RCC with a compromised ATP production ([@B196]). The accumulation of Aβ peptides or of the precursor APP inside the mitochondria ([@B3]; [@B90]) and even the interaction of Aβ peptides with some component of the mitochondrial matrix ([@B134]) would be the most straightforward and rational explanations to justify the mitochondrial dysfunctions in the animal models of AD. However, mitochondria lack APP and the set of the enzymes required for Aβ peptide generation, making a mitochondria-localized production of Aβ peptides unlikely. Furthermore, a solid mechanism that explains the mitochondrial import of Aβ peptides and the direct negative effects of Aβ peptides on mitochondria is still missing, suggesting that the mitochondrial dysfunctions identified in all these AD models are indirect effects of Aβ peptides. In support of this point, a recent study showed that Aβ peptides impaired mitochondrial import of nuclear-encoded precursor proteins due to an extra mitochondrial co-aggregation process ([@B26]).

Tauopathies including AD are also characterized by mitochondrial dysfunction. Tau influences, directly and indirectly, the mitochondrial transport along the neuronal axon and the mitochondrial functions. This leads to the reduction and impairment of mitochondria at the presynaptic terminals with obvious deleterious consequences ([@B58]; [@B59]). In AD brains, phosphorylated tau was found interacting with VDAC1 leading as well to mitochondrial dysfunction ([@B137]). Hyperphosphorylation of tau negatively affects complex I activity with a decrease of ATP production, an increase of oxidative stress, dissipation of mtΔΨ, induction of the mitochondrial fission, and excessive mitochondrial fragmentation in postmortem brains from AD patients and in murine models ([@B135]; [@B64]). In addition, mitochondrial stress was shown to promote tau-hyperphosphorylation in a mouse model ([@B148]). These observations argue for a prominent role of tau pathology in the mitochondrial dysfunction of AD.

The Translocase of outer membrane 40 kDa submit homolog (Tomm40) is a mitochondrial channel localized in OMM that is fundamental for the import of nuclear-encoded mitochondrial preproteins ([@B27]). Aβ peptides affected directly or indirectly the mitochondrial import machinery including Tomm40, and this may also contribute to the mitochondrial dysfunction observed in AD ([@B48]; [@B4]; [@B26]). *TOMM40* gene is contained in a tight gene cluster together with APOE gene in the chromosome 19 ([@B84]; [@B222]). APOE is one of the most significant genetic risk factors for late-onset sporadic AD (LOAD) with the ε4/ε4 isoform linked to the highest risk ([@B202]). It seems that also a variable-length, deoxythymidine homopolymer polymorphism in intron 6 of the *TOMM40* gene represents a genetic risk for LOAD. However, different groups showed that *TOMM40* SNPs (single-nucleotide polymorphisms) are associated with the LOAD ([@B142]; [@B229]; [@B111]; [@B40]). In a Caucasian ethnic group three variants of the *TOMM40* polymorphisms were identified, and the variant rs10524523 has received particular attention since it lowered the age of LOAD onset by 7 years in APOE3/4 carriers ([@B193]). Furthermore, this variant was associated with impaired cognition and the gray matter volume in the brain area susceptible to AD ([@B102]). Different groups also demonstrated the strong influence of *TOMM40* "523" variant on *TOMM40* and *APOE* genes transcription ([@B126]; [@B165]).

The integration of all these facts into a significant biological context like neuronal cells in AD, suggests that the accumulation of dysfunctional mitochondria at the synapses and the lack of their replacement would contribute substantially to the neurons degeneration and consequently to the worsening of the AD condition.

Mitochondrial therapies in AD {#s4}
=============================

AD is still without a cure and also essentially lacks a rational understanding of the primary event triggering the disease. Nevertheless, an improved comprehension of this deleterious disorder and the development of effective treatments are essential not only to heal the disease but also eventually to prevent or postpone the onset of the symptoms in the patients.

The traditional cures used nowadays to treat the AD patients are so far the cholinesterase inhibitors (**donepezil**, **rivastigmine**, and **galantamine**) and **memantine** that block the N-methyl-D-aspartate (NMDA) receptor and the excess of glutamate activity. NMDA receptors and acetylcholin (Ach) are fundamental in memory and learning processes and their concentration and function are compromised in AD ([@B74]). However, these treatments improve the cognitive and memory functions, without really slowing down the progression of the disease.

As described above, mitochondrial dysfunctions and a compromised energetic metabolism are two prominent aspects of AD pathology. Therefore, mitochondria should be seriously considered as pharmacological targets. In the course of history, nevertheless, different compounds affecting mitochondria were already tested in AD without a successful outcome. However, as the idea of AD as a multifactorial disease gained more ground in the last years, a reconsideration of mitochondria as a valid therapeutic target together with other medications is strongly recommended.

Mitochondria could be targeted through two ways: i) by pharmacologic approaches acting on mitochondria directly or ii) by action on the lifestyle that indirectly hits this organelle ([**Figure 2**](#f2){ref-type="fig"}). In the following section, we describe the most popular mitochondrial treatments that have been used until today on AD patients, and in [**Table 1**](#T1){ref-type="table"}, we summarize specifically the beneficial effects of these compounds on mitochondria in different experimental AD models. The table is also a proof that these treatments are able to act effectively and positively on mitochondria, and therefore a revision and improvement of their use in AD would be worthy.

![Schematic summary of mitochondrial-targeted therapies used in AD models and clinical trials.](fphar-10-00902-g002){#f2}

###### 

List of compounds and lifestyle activities effects on mitochondria in experimental models for AD.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Treatment                                   Effect on mitochondria                                                                                                                                          Experimental AD models                                                                   References
  ------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------- ----------------------------------------------------------------------
  **Antioxidants**                                                                                                                                                                                                                                                                                     

  *Vitamin E*                                 Increase mtΔΨ and ATP\                                                                                                                                          *In vitro* glutamate-injured astrocytes\                                                 ([@B207]; [@B205])
                                              ROS scavenger\                                                                                                                                                  *In vivo* aged old mice                                                                  
                                              Reduction of lipid peroxidation                                                                                                                                                                                                                          

  *Selenium*                                  Inhibition of ROS production and oxidative damage\                                                                                                              *In vitro* Aβ*~42~*-*CFP*-overexpressed HEK293 cell line\                                ([@B31]; [@B10])
                                              Reduction of mitochondrial membrane depolarization                                                                                                              In vivo scopolamine-treated aged rats                                                    

  *Vitamin C*                                 Maintenance of mitochondrial integrity through reduction of oxidative damage\                                                                                   *In vitro* Aβ~1-42~ peptide-treated human cortical neurons\                              ([@B147]; [@B116]; [@B49])
                                              Reduction of mitochondrial membrane depolarization and mitochondria-mediated apoptosis                                                                          *In vivo* 5XFAD Tg mice\                                                                 
                                                                                                                                                                                                              *In vivo* APP/PSEN1 mice                                                                 

  *Coenzyme Q10*                              Attenuation of decreased oxidative phosphorylation efficiency and of increased H~2~O~2~ production\                                                             Isolated mitochondria from Aβ~1-40~ peptide-treated diabetic Goto--Kakizaki aged rats\   ([@B151]; [@B60]; [@B68]; [@B199]; [@B61])
                                              Reduction of mitochondrial accumulation of Aβ peptide\                                                                                                          *In vitro* Aβ~25-35~ peptide-treated HUVEC cell line\                                    
                                              Prevention of Aβ peptide-induced mPTP opening\                                                                                                                  *In vitro* Aβ~1-42~ peptide-treated M17 cell line\                                       
                                              Protection against dissipation of mtΔΨ\                                                                                                                         *In vivo* TgP301S mice\                                                                  
                                              Beneficial effect of mitochondrial ETC                                                                                                                          *In vivo* Tg19959 mice                                                                   

  *Mitoquinone (MitoQ)*                       Prevention of increased ROS production, loss of mtΔΨ, decreased GSH/GSSG ratio, increased MDA and 3-NT\                                                         *In vitro* Aβ~22-35~ peptide-treated mouse cortical neurons and N2a cell line\           ([@B136]; [@B146]; [@B155])
                                              Regulation of mitochondrial fusion, fission, and matrix genes\                                                                                                  *In vivo* 3xTg-AD and Tg2576 mice\                                                       
                                              Protection of mitochondrial structure\                                                                                                                          *In vivo* human Aβ-overexpressed *C. elegans*                                            
                                              Amelioration of ATP production, COX activity, and depletion of the cardiolipin                                                                                                                                                                           

  *SkQ1*                                      Preservation of mitochondrial structure\                                                                                                                        *In vivo* OXYS rats                                                                      ([@B132]; [@B219]; [@B115])
                                              Improvement of mitochondrial biogenesis\                                                                                                                                                                                                                 
                                              Increase of COX activity\                                                                                                                                                                                                                                
                                              Inhibition of ROS production\                                                                                                                                                                                                                            
                                              Reduction of mtDNA deletion                                                                                                                                                                                                                              

  *MitoApo or apocynin*                       Protection against oxidative stress-induced cell death\                                                                                                         *In vitro* 6-OHDA-treated LUHMES cell line                                               ([@B19])
                                              Reduction of superoxide production                                                                                                                                                                                                                       

  *Astaxanthin*                               Prevention of mitochondrial H~2~O~2~ production                                                                                                                 *In vitro* Aβ~1-42~ oligomers-treated mouse hippocampal neurons                          ([@B129])

  *Melatonin*                                 Restoration of: respiration rate, RCC proteins expression, mtΔΨ, ROS production, ATP levels\                                                                    Isolated mitochondria from APPswe and APP/PSEN1 mice\                                    ([@B51]; [@B53]; [@B54]; [@B166]; [@B192]; [@B80]; [@B195]; [@B242])
                                              Prevention of decreased mitochondrial volume\                                                                                                                   *In vitro* APPswe-overexpressed HEK293 cell line\                                        
                                              Improvement of mitochondrial biogenesis factors expression and mtDNA/nuDNA ratio\                                                                               *In vitro* Aβ~22-35~ peptide-treated cultured rat hippocampal neurons\                   
                                              Amelioration of mitochondrial membrane fluidity and mitochondrial structure\                                                                                    *In vitro* Aβ peptide-treated NARP cybrids cell line\                                    
                                              Stabilization of cardiolipin and mPTP\                                                                                                                          *In vivo* OXYS rats\                                                                     
                                              Decrease of mitochondrial Ca^2+^ levels                                                                                                                         *In vivo* injection of Aβ~1-42~ peptide in rats hippocampus\                             
                                                                                                                                                                                                              *In vivo* APP/PSEN1 mice                                                                 

  *α-Lipoic acid (LA)*                        Decrease of oxidative stress and apoptotic markers\                                                                                                             *In vitro* AD fibroblast\                                                                ([@B150]; [@B1]; [@B140])
                                              Preservation of COX assembly\                                                                                                                                   *In vivo* aged rats\                                                                     
                                              Elevation of ATP levels, Krebs cycle dehydrogenase, complex I, and COX activities                                                                               *In vitro* Aβ~1-42~ peptide-treated differentiated SH-SY5Y cell line\                    
                                                                                                                                                                                                              *In vivo* ApoE4 Tg mice                                                                  

  *N-Acetyl-cysteine (NAC)*                   Decrease oxidative stress and apoptotic markers\                                                                                                                *In vitro* AD fibroblast                                                                 ([@B150])
                                              Preservation of COX assembly                                                                                                                                                                                                                             

  *Ginkgo biloba*                             Stabilization of mtΔΨ and ATP production\                                                                                                                       *In vitro* APPmutant-overexpressed and Aβ peptide-treated PC12 cell line\                ([@B62]; [@B63]; [@B187]; [@B232]; [@B109])
                                              Reduction of ROS/RNS production\                                                                                                                                *In vitro* Aβ~25-35~ peptide-treated IMR-32 and SH-SY5Y cell line\                       
                                              Increase of mitochondrial APE1 levels\                                                                                                                          *In vitro* APP-overexpressed SH-SY5Y cell line\                                          
                                              Enhancement of complex I, III, COX activities\                                                                                                                  *In vivo* Aβ~25-35~ peptide-injected rats                                                
                                              Improvement of oxygen consumption\                                                                                                                                                                                                                       
                                              Up-regulation of mitochondrial DNA\                                                                                                                                                                                                                      
                                              Block of mitochondria-mediated apoptosis                                                                                                                                                                                                                 

  *Szeto-Schiller tetrapeptides 31 (SS31)*    Increase of mitochondrial biogenesis and dynamics proteins level\                                                                                               *In vitro* primary neurons from Tg2576 mice\                                             ([@B136]; [@B24]; [@B180], [@B182])
                                              Rescue of mitochondrial anterograde transport\                                                                                                                  *In vitro* Aβ~22-35~ peptide-treated\                                                    
                                              ROS scavenger and reduction of H~2~O~2~ and lipid peroxidation levels\                                                                                          or APPswe and APPInd-overexpressed N2a cell line\                                        
                                              Prevention of mPTP, mitochondrial swelling, and mitochondria-mediated apoptosis\                                                                                *In vivo* Tg2576 mice                                                                    
                                              Protection of mitochondrial structure\                                                                                                                                                                                                                   
                                              Increase of ATP production and supply at nerve terminals\                                                                                                                                                                                                
                                              Increase of COX activity, and mtΔΨ\                                                                                                                                                                                                                      
                                              Increase of mtDNA copy number and mitochondrial network                                                                                                                                                                                                  

  *Catalase*                                  Reduction of abnormal APP process, oligomeric Aβ peptides, and BACE1 activity and levels, and oxidative damage\                                                 *In vivo* MCAT/APP mice                                                                  ([@B139])
                                              Increase of protective soluble APPα and CTF83 fragments                                                                                                                                                                                                  

  **Phenylpropanoids**                                                                                                                                                                                                                                                                                 

  *Resveratrol*                               Attenuation of ROS accumulation, mtΔΨ, and mitochondria-mediated apoptosis\                                                                                     *In vitro* Aβ peptide-treated PC12 cell line\                                            ([@B99]; [@B173]; [@B47]; [@B244])
                                              Increase of COX levels\                                                                                                                                         *In vivo* APP/PSEN1 mice                                                                 
                                              Stimulation of mitophagy/autophagy                                                                                                                                                                                                                       

  *Quercetin*                                 Restoration of mtΔΨ, ROS production, and ATP levels, and the normal mitochondrial morphology\                                                                   *In vivo* APP/PSEN1 mice\                                                                ([@B243]; [@B100]; [@B210]; [@B83])
                                              Increase MnSOD activity\                                                                                                                                        *In vitro* Aβ peptide-treated rat hippocampal neurons\                                   
                                              Prevention of mitochondria-mediated apoptosis                                                                                                                   *In vitro* OA-treated HT22 hippocampal neurons\                                          
                                                                                                                                                                                                              *In vivo* aluminum-treated rats                                                          

  *Wogonin*                                   Rescue the mtΔΨ loss\                                                                                                                                           *In vitro* Tet-On Aβ42-GFP-overexpressed SH-SY5Y cell line\                              ([@B95])
                                              Attenuation of mitochondria-mediated apoptosis                                                                                                                  *In vivo* 3xTg-AD mice                                                                   

  *Epigallocatechin-3-gallate (EGCG)*         Attenuation of ROS accumulation\                                                                                                                                Isolated mitochondria from hippocampus, cortex, and striatum of APP/PSEN1 mice\          ([@B55]; [@B14]; [@B263])
                                              Increase of MnSOD level\                                                                                                                                        *In vitro* APP695-overexpressed N2a cell line\                                           
                                              Restoration of altered mtΔΨ~t~, ATP levels, and mitochondria respiratory rates                                                                                  *In vitro* APPmut-overexpressed neuroblastoma cell line\                                 
                                                                                                                                                                                                              *In vivo* streptozotocin-infused Wistar rats                                             

  *Curcumin*                                  Increase of ATP levels and COX activity\                                                                                                                        *In vitro* Aβ~22-35~ peptide-treated SH-SY5Y cell line\                                  ([@B217]; [@B28]; [@B89]; [@B80]; [@B181])
                                              Positive effect on mtΔΨ and respiratory control ratio\                                                                                                          *In vitro* glutamate-treated PC12 cell line\                                             
                                              Reduction of ROS production and mitochondria-mediated apoptosis\                                                                                                *In vivo* APP751SL mice\                                                                 
                                              Restoration of complex I, II, COX levels and activities                                                                                                         *In vivo* APP/PSEN1 mice\                                                                
                                                                                                                                                                                                              *In vivo* aluminum-treated rats                                                          

  **Action of the life style**                                                                                                                                                                                                                                                                         

  *Calories restriction*                      Decrease of F~0~F~1~-ATPase activity                                                                                                                            *In vivo* P301L mice                                                                     ([@B45])

  *Oleuropein aglycone (OLE)*                 Stimulation of mitophagy/autophagy                                                                                                                              *In vivo* TgCRND8 mice                                                                   ([@B86]; [@B163])

  *Hydroxytyrosol (HT)*                       Reduction of mitochondrial carbonyl protein\                                                                                                                    *In vivo* APP/PSEN1 mice\                                                                ([@B167]; [@B159])
                                              ROS scavenger\                                                                                                                                                  *In vitro* copper-treated SH-SY5Y cell line                                              
                                              Enhancement of MnSOD level                                                                                                                                                                                                                               

  *Ketones*                                   Increase of TCA cycle intermediates and ATP hydrolysis\                                                                                                         *In vivo* 3xTg-AD mice                                                                   ([@B164])
                                              Reduction of mitochondrial redox potential (free mitochondrial \[NAD^+^\]/\[NADH\] ratio oxidation)                                                                                                                                                      

  *Physical exercise (PE)*                    Increase of mitochondrial mass, mtΔΨ, complexes I, COX, αKGDH, and ATP synthase activities\                                                                     Isolated mitochondria from APP/PSEN1 mice\                                               ([@B17]; [@B113])
                                              Reduction of ROS production and mtDNA oxidative damage\                                                                                                         *In vivo* swimming-trained pregnant rats\                                                
                                              Restoration of mitochondrial antioxidant enzymes and OGG1 activities\                                                                                           *In vivo* 3xTg-AD mice                                                                   
                                              Suppression of OGG1 and MnSOD acetylation\                                                                                                                                                                                                               
                                              Modulation of mitochondrial dynamics proteins (Mfn1 and Drp1)                                                                                                                                                                                            

  *2-deoxyglucose*                            Increase of αKGDH level\                                                                                                                                        *In vivo* 3xTg-AD mice\                                                                  ([@B87]; [@B257])
                                              Reduction of mitochondrial APP and Aβ oligomer level, mitochondrial stress response proteins levels, mtΔΨ                                                       *In vivo* Aβ peptides-treated adult rats                                                 

  *Rapamycin*                                 Prevention of decrease of mtΔΨ\                                                                                                                                 *In vitro* Aβ~1-42~ peptide-treated PC12 cell line                                       ([@B256])
                                              Stimulation of mitophagy/autophagy                                                                                                                                                                                                                       

  *Spermidine, Urolithin A, Actinonin*        Stimulation of mitophagy/autophagy                                                                                                                              *In vivo* Aβ and tau *Caenorhabditis elegans* models\                                    ([@B71])
                                                                                                                                                                                                              *In vivo* APP/PSEN1 mice                                                                 

  **Other mitochondrial-based therapy**                                                                                                                                                                                                                                                                

  *Nicotinamide adenine dinucleotide (NAD)*   Prevention of OCR deficits\                                                                                                                                     *In vitro* APP/PSEN1-overexpressed hippocampal neuroblastoma\                            ([@B130]; [@B247]; [@B71])
                                              Promotion of PGC-1α level\                                                                                                                                      *In vitro* NMN-treated organotypic hippocampal slice cultures (OHCs)\                    
                                              Restoration of NAD^+^ and ATP level\                                                                                                                            *In vivo* APP/PSEN1 mice\                                                                
                                              Changes of mitochondrial dynamics fusion--fission\                                                                                                              *In vivo* Aβ oligomer-infused rats\                                                      
                                              Block of ROS accumulation\                                                                                                                                      *In vivo* Tg2576 mice\                                                                   
                                              Stimulation of mitophagy/autophagy                                                                                                                              *In vivo* Aβ and tau *Caenorhabditis elegans* models                                     

  *Pioglitazone*                              Restoration of mitochondrial energy metabolism and activity                                                                                                     Isolated mitochondria from APP/PSEN1 mice\                                               ([@B29], [@B30])
                                                                                                                                                                                                              *In vitro* APP695-overexpressed CHO cell line                                            

  *Dimebon (Latrepirdine)*                    Increase and maintenance of succinate dehydrogenase and RCC activities, mtΔΨ, ATP levels, TIM and TOM proteins levels, mitochondrial dynamics and morphology\   Isolated mitochondria from rat\                                                          ([@B262]; [@B154]; [@B66]; [@B251])
                                              Attenuation of Ca^2+^ induced mitochondrial swelling\                                                                                                           *In vitro* mouse cortical neurons and SH-SY5Y\                                           
                                              Restoration of impaired autophagy/mitophagy and mPTP proteins levels                                                                                            *In vitro* APPswe-overexpressed HEK293 cell line\                                        
                                                                                                                                                                                                              *In vitro* glutamate-treated CGNs                                                        
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AD, Alzheimer's disease; ETC, electron transport chain; RCC, respiratory chain complexes, mtΔΨ: mitochondrial membrane potential; OCR, oxygen consumption rates; ATP, adenosine triphosphate; mPTP, mitochondrial permeability transition pore; mtDNA, mitochondrial deoxyribonucleic acid; nuDNA, nuclear deoxyribonucleic acid; APE1, apurinic/apyrimidinic endonuclease 1; MnSOD, manganese superoxide dismutase; OGG1, oxoguanine DNA glycosylase-1; αKGDH, α-ketoglutarate dehydrogenase; COX, cytochrome c oxidase or complex IV; TIM, translocase inner membrane; TOM, translocase outer membrane; Mfn1, mitofusin-1; Drp1, dynamin-1-like protein; PGC-1α, peroxisome-proliferator-activated receptor γ coactivator-1α; NAD, nicotinamide adenine dinucleotide; NADH, reduced nicotinamide adenine dinucleotide; ROS, reactive oxygen species; RNS, reactive nitrogen species; GSH, glutathione; GSSG, oxidized glutathione; 3-NT, 3-nitrotyrosine; MDA, malondiaaldehyde; SelM, selenoprotein M; 6-OHDA, 6-hydroxydopamine; OA, okadaic acid; H~2~O~2~, hydrogen peroxide; NMN, nicotinamide mononucleotide; Aβ, β-amyloid peptide; AβPP, β-amyloid precursor protein; PS1, presenilin 1; BACE1, β-secretase-1; HEK293, human embryonic kidney 293 cell lines; HUVEC, human umbilical vein endothelial cell line; M17, human neuroblastoma cell line; N2a, mouse neuroblastoma cell line; LUHMES, Lund human mesencephalic cell line; SH-SY5Y, human neuroblastoma cell lines; IMR-32, human neuroblastoma cell lines; PC12, pheochromocytoma of rat adrenal medulla-derived cell lines; OHCs, organotypic hippocampal slice cultures; NARP, cybrid cell lines bearing mtDNA mutation T8993G; CGN, cerebellar granule neurons; 5xFAD, mice expressing human APP and PSEN1 genes with a total of five AD-linked mutations, the Swedish, Florida, and London mutations in APP, and the M146L and L286V mutations in PSEN1; APP/PSEN1, mice contain human APP gene bearing the Swedish mutation and PS1 gene containing L166P mutation; TgP301S, mice expressing mutant human microtubule-associated protein tau (MAPT); Tg19959, mice expressing human APP gene bearing the Swedish mutation and Indiana mutation; TgCRND8, mice expressing human APP695 gene with the Swedish mutation and Indiana mutation; 3xTg-AD, mice contain three mutations (Swedish, MAPT, PS1) associated with familial AD; Tg2676 mice, mice expressing mutant human form of APP (isoform 695) with Swedish mutation; APP751SL, mice expressing the human APP bearing both Swedish and the London mutation; ApoE4 Tg mice, mice expressing human apolipoprotein E (APOE) gene; OXYS rats, senescence-accelerated rats; MCAT, mitochondria-targeted catalase; C. elegans, Caenorhabditis elegans.

More information about the ongoing clinical trials concerning mitochondria in AD are summarized in Wilkins et al. and in Perez Ortiz et al. ([@B168]; [@B253]), and they can also be found in [www.clinicaltrials.gov](www.clinicaltrials.gov).

Antioxidants {#s4_1}
------------

Since the increased oxidative stress accompanied by the reduction of the antioxidant power was measured in the brain, CSF, and blood from AD patients, treatments with antioxidant compounds were tested to counteract this oxidative unbalance and slow down the progression of the AD symptoms.

Typical antioxidants were the **vitamins**, **E** and **C**, but their effects in the context of AD remain questionable. For example, in two studies with vitamin E, some markers of lipid peroxidation were found decreased in AD patients' CSF, with no consistent effect on or even a deterioration of cognitive functions ([@B7]; [@B76]). Vitamin E was also administered in combination with **selenium**. However, high levels of selenium were found toxic with a pro-oxidant effect, glial activation, and neuronal death ([@B240]). There is an important study called **PREADViSE** that was performed to see the long-term effect of anti-oxidant supplements (Vitamin E, selenium, Vitamin E + selenium or placebo) on dementia incidence among asymptomatic men. However, the supplement did not prevent dementia occurrence ([@B118]).

Targeting directly the mitochondria with antioxidant compounds was always one of the most considered therapeutic strategies in AD. In this regard, an antioxidant directed to mitochondria that has been tried was the **coenzyme Q10** (**CoQ10**). CoQ10 has a quinone structure and is a component of the mitochondrial RCC. In a rat model for AD, CoQ10 prevented the cognitive decline ([@B44]). Still, due to a low bioavailability in the brain ([@B119]), CoQ10 has never been successful in humans. To overcome this issue, the **mitoquinone mesylate** (**MitoQ**) was optimized. MitoQ is an antioxidant compound made of ubiquinone conjugate with triphenylphosphonium (TPP). The TPP is necessary to target the molecule to the mitochondria because it helps to cross the lipid bilayers accumulating on the negative site of mitochondrial membranes ([@B110]; [@B214]). MitoQ behaved as ROS scavenger and was tested in different AD model systems (see [**Table 1**](#T1){ref-type="table"}). Here, MitoQ shown to prevent oxidative damage, to protect RCC activity, to reduce Aβ peptide levels, synaptic loss, and astrogliosis, and to improve cognitive functions ([@B146]; [@B155]). As reported in the review from Ortiz ([@B168]), at the moment, MitoQ is tested in a small clinical trial to check its effect on cerebrovascular blood flow in AD. Similarly to MitoQ, other antioxidant compounds (**SkQ1**, **MitoApo**, **astaxanthin**) affect positively the mitochondrial functions (see [**Table 1**](#T1){ref-type="table"}) and could be potentially used to treat AD ([@B129]; [@B219]; [@B19]).

Another group of antioxidant molecules such as **melatonin**, **α-lipoic acid (LA)**, **N-Acetyl-cysteine (NAC)**, and ***Ginkgo biloba*** were tested *in vivo* and *in vitro* and showed protective effects on Aβ peptide accumulation and mitochondrial toxicity as well as on cognitive functions ([@B51]; [@B191]). **Melatonin** is a neurohormone produced by the pineal gland with neuroprotective functions in AD pathogenesis ([@B213]). Melatonin is a ROS scavanger and showed some anti-amyloidogenic properties ([@B51]; [@B191]). At mitochondrial level, melatonin prevented the ROS production, the cardiolipin oxidation, and the mPTP opening, restored the Ca^2+^ balance, and reduced the caspase-3 and -9 levels ([@B72]; [@B103]; [@B170]; [@B70]). Treatments with **α-lipoic acid**, a cofactor for many RCC enzymes, exhibited a positive effect on cognitive functions in clinical trials on AD patients and in murine models of aging and AD, α-lipoic acid affected also the formation and the stabilization of Aβ peptide fibril as well as the protection against the Aβ peptide toxicity in cultured hippocampal neurons ([@B127]; [@B133]; [@B160]; [@B88]; [@B178]; [@B200]). **N-Acetyl-cysteine** (**NAC**) is the precursor of the endogenous antioxidant glutathione (GSH), a key molecule for the maintenance of mitochondrial functions ([@B233]). *In vitro* and *in vivo*, NAC had beneficial effects on Aβ peptide and phosphorylated tau levels with improvement of cognitive functions, protection against memory decline, and reduction of oxidative stress markers (see also [**Table 1**](#T1){ref-type="table"}) ([@B221]; [@B75]; [@B96]; [@B39]). In two clinical trials, subjects with MCI, AD, or early memory loss were treated for a long time with a nutraceutical formulation that also included NAC. Improvement of cognitive and behavioral functions was observed ([@B185]; [@B186]). ***G. biloba*** is a natural antioxidant already used in the Chinese traditional medicine. [**Table 1**](#T1){ref-type="table"} shows all the effects of *G. biloba* on mitochondrial functions. Two clinical trials were performed to test the effect of *G. biloba* in the prevention against memory and cognitive decline in older adults and AD subjects. Unfortunately, no positive effects were observed in these tests ([@B215]; [@B237]).

The **Szeto-Schiller** (**SS**) **tetrapeptides** are a group of small peptides that due to their structure act as antioxidants and can reach the mitochondrial matrix and the IMM ([@B227]). In one of AD murine models, the **SS31** reduced Aβ peptide production, mitochondrial dysfunction, and enhanced mitochondrial biogenesis and synaptic activity ([@B24]; [@B180]). Recently, a combination of SS31 and the mitochondrial division inhibitor 1 (Mdivi1) was tested in cultured AD cells with positive effects, suggesting that a combined treatment of mitochondria-targeted antioxidants could have higher effectiveness ([@B182]).

An interesting preclinical study proposed to target the antioxidant enzyme **catalase** to the mitochondria. Catalase catalyzes the decomposition of hydrogen peroxide (H~2~O~2~) in water (H~2~O) and oxygen (O~2~) and is typically localized in the peroxisome. A double transgenic mouse with mitochondria-targeted catalase (MCAT) and APP was created, and the protective effects against abnormal APP processing, Aβ peptide pathology, and lifespan extension were tested. Mitochondrial catalase showed beneficial outcomes in this highly artificial model. Although most of the antioxidant clinical trials were not entirely successful, this study proved that a direct target of an antioxidant to the mitochondria might still have a chance as a therapeutic approach in AD ([@B139]).

Despite the oxidative stress unbalance is an evident hallmark in AD and some mitochondrial-targeted antioxidant strategies showed promising effect on cognitive functions, none entered so far in the market as a valid AD treatment. There are different reasons to justify the failures (summarized in Persson et al. paper; [@B169]). The antioxidants at certain concentrations and conditions could behave as pro-oxidants and therefore they are more harmful than useful. The antioxidant administration during the clinical trials was probably started too late during the development of the disease suggesting that an early intervention could be more effective. Last, the antioxidant bioavailability in the brain could be low due to the difficulty of these molecules to cross the blood--brain barrier (BBB) requiring a rational modification of their structure to overpass this issue.

Phenylpropanoids {#s4_2}
----------------

The **phenylpropanoids** are natural compounds that exert many physiological functions crucial for the survival of plants. In this heterogeneous group of substances, many subclasses have been identified such as stilbenoids, flavonoids, curcuminoids, phenolate esters, and lignans. These compounds showed an effect against the Aβ peptide and tau pathologies, on the activation of the inflammation response, on the oxidative stress, and also on the mitochondrial dysfunction ([@B114]). Between others, **resveratrol**, **quercetin**, **wogonin**, **epigallocatechin-3-gallate** (**EGCG**), and **curcumin** were already tested and showed to promote mitochondrial biogenesis, to impede apoptotic pathways through inhibition of DNA fragmentation, ROS formation, and caspase-3 activation, and to reduce perturbation of mtΔΨ and ATP levels (see also [**Table 1**](#T1){ref-type="table"} for the effects of phenylpropanoids on mitochondria in AD models) ([@B120]; [@B41]; [@B97]; [@B235]; [@B181]). Furthermore, these compounds were able to restore the mitochondrial functions in a transgenic mouse model of AD ([@B55]). In particular in an *in vitro* study, **EGCG**, a major flavonoid component of the green tea, accumulated in mitochondria and exerted a strong influence on the mitochondrial functions proposing it as pharmacological treatment in AD ([@B206]; [@B55]). However, phenylpropanoids have a dual effect on mitochondrial function, depending on the concentration. For example, EGCG could increase apoptosis in cultured neurons at specific concentrations, while quercetin protected cultured hippocampal cells against Aβ peptide-induced apoptosis only in low concentrations ([@B33]; [@B5]). **Curcumin** is an antioxidant compound with massive potential for the prevention and treatment of AD. It showed beneficial effects on Tg2576 AD model mice, such as reduction of the brain oxidative stress and the neuroinflammation, but no effect in AD patients, probably due to a low bioavailability ([@B124]; [@B11]; [@B189]). New strategies have been implemented to overpass this limitation and improve the curcumin pharmacokinetics, such as the nanotechnology-based delivery system, new pharmaceutical formulations, and the change in the way of administration ([@B179]; [@B208]).

Like the antioxidant, the use of the phenylpropanoids in AD treatment needs to be considered with caution and none of them has become a real therapy yet. The new AD clinical trials based on this group of molecules definitely require a broad design, a substantial revision, and a careful implementation.

Action on the Lifestyle {#s4_3}
-----------------------

### Calories Restriction, Diet, Exercises {#s4_3_1}

Lifestyle activities, in particular **exercise** and **diet**, have been known to act at the mitochondrial level and should therefore be considered as possible interventions to treat AD. [**Table 1**](#T1){ref-type="table"} reports the effects of the compounds and activities strictly related to the lifestyle on mitochondria from AD models.

A **Mediterranean diet** has been correlated to the reduction of the incidence of AD ([@B203]; [@B107]). The Mediterranean diet is mainly composed of fruits, vegetables, and omega-3 fatty acids, which are enriched in olive oil. It was observed that, for example, **polyphenol-rich extra-virgin oil** reduced mitochondria-generated oxidative stress and insulin resistance in high-fat diet fed rats ([@B121]). Another polyphenol component of olive oil called **oleuropein aglycone** (**OLE**) promoted autophagy, decreased aggregated proteins levels, and reduced the cognitive impairment in AD patients' brain ([@B86]; [@B38]). **Hydroxytyrosol** (**HT**), another bioactive compound of olive oil, ameliorated mitochondrial dysfunction in an animal model of AD ([@B167]). On the other side, higher consumption of **fructose** affected negatively the mitochondrial function in hippocampus from adult rats, suggesting that fructose consumption should be actively avoided ([@B34]). **Ketones** are another source of energy for the brain when there is a limited amount of available glucose ([@B161]). The ketone ester diet in a model of AD (3xTgAD) had positive effects also on mitochondrial functions ([@B164]). The therapeutic ketosis was suggested to reduce the AD brain pathology including the accumulation of Aβ plaques and NFT ([@B108]). Of course, the results obtained in AD murine models have to be proven in humans through clinical trials ([@B175]). In this regard, there are experiments going on at the University of Kansas about the effect of a ketogenic diet (KD) on participants with AD, but no definitive results are available yet ([@B230]; [@B231]).

An extreme form of diet is represented by **calorie restriction** (**CR**). CR is a strong limitation on calorie intake without facing a lack of nutrients. It is well known that CR is an excellent way to extend lifespan, to increase insulin sensitivity, and to prevent age-related diseases ([@B143]). At the mitochondrial level, CR showed positive effects by affecting mitochondrial biogenesis through the induction of NO synthetase (eNOS) ([@B156]). Newly synthesized mitochondria led to an increase of mitophagy, reduction of ROS, increased ATP levels, and overall improvement of the mitochondrial quality and cell bioenergetics ([@B131]). Furthermore, CR affected the mtDNA content as well as the amount of TFAM-bound mtDNA in rats ([@B172]). There are ongoing clinical studies around the world concerning the effect of CR and dietary intervention on MCI ([@B253]).

**Physical exercise** (**PE**) has been demonstrated to generally benefit the health of the body and mind, affecting properties such as brain plasticity and cognitive function. Hence, it could be a good prevention for age-related diseases ([@B93]; [@B162]). It is well known that PE targets mitochondria and improved mitochondrial function (see [**Table 1**](#T1){ref-type="table"} to check the effects of PE on mitochondria in AD models). A study showed that PE increased mtDNA repair, ameliorated mitochondria respiratory function through the increase of RCC activity, attenuated ROS generation capacity together with a reduction of Aβ~1-42~ peptide levels, and correlated with an amelioration of cognitive function in the hippocampus from the APP/PS1 transgenic mouse model of AD ([@B17]). However, data obtained in another AD mouse model (3xTg-AD) demonstrated that short-term exercise did not augment the critical gene expression of mitochondrial biogenesis, even if the glucose metabolism was overall improved ([@B50]). Maternal exercise during pregnancy resulted in a positive effect on mitochondrial function concerning the onset of AD. In this study, a protective effect against Aβ oligomer-induced neurotoxicity in the adult offspring brain rats was shown ([@B113]). Clinical trials with PE were performed in older adults with healthy as well as impaired cognitive function. Aβ~1-42~ concentration in plasma and CSF was modified. In the brain, improvements of cognitive and executive functions, and even a change of hippocampal volume and memory, were observed, together with a reduced brain atrophy ([@B9]; [@B69]; [@B239]; [@B260]). Of course, in these human studies, neither a direct effect of PE on mitochondria nor the molecular mechanisms of PE benefits have been proved. However, all the studies performed in animal models positively supported the hypothesis that PE may have a beneficial effect on mitochondrial functions and glucose metabolism also in humans.

Diet, CR, and PE can also be combined to improve the quality of human aging and to prevent neurodegenerative disease ([@B184]). These approaches were shown to affect mitophagy, the cellular removal mechanism for damaged mitochondria, indicating the mitophagy as a new and promising therapeutic target to prevent the progression of the diseases. Experimental evidences from rodent studies showed that fasting and exercises could have a beneficial effect not only on mitophagy but also on mitochondrial biogenesis, reduction of oxidative stress, and overall neuronal plasticity ([@B2]). Other strategies to boost mitophagy in order to delay AD are the use of compounds like **2-deoxyglucose**, which protects neurons and enhances mitochondrial functions ([**Table 1**](#T1){ref-type="table"}) ([@B57]; [@B257]). Additional molecules that promote autophagy/mitophagy are **rapamycin**, **spermidine**, **urolithins**, and the antibiotic **actinonin** ([@B218]; [@B153]; [@B198]; [@B71]). The mTOR inhibitor rapamycin was already demonstrated to have beneficial effects on a mouse AD model ([@B218]). Testing these molecules in clinical AD might be worth it.

Other Mitochondria-Based AD Therapy {#s4_4}
-----------------------------------

### Oxaloacetate {#s4_4_1}

Treatment with **oxaloacetate** (**OOA**), an intermediate of the Krebs cycle and gluconeogenesis, has been proposed as a new therapeutic approach for AD, and it was already tested in some AD subjects ([@B224]). Studies involving OOA performed in mice showed positive effects on glycolysis, respiratory fluxes, mtDNA and mtDNA-encoded proteins, activation of mitochondrial biogenesis, hippocampal neurogenesis activity, neuroinflammation, and change in brain insulin signaling ([@B254]). Despite there are no studies about the direct efficacy of OOA treatment on mitochondria in AD models, clinical trials with OOA in AD are ongoing.

### NAD {#s4_4_2}

Nicotinamide adenine dinucleotide (NAD) is an intermediate common to several mitochondrial metabolic pathways such as glycolysis, TCA cycle, and oxidative phosphorylation. Studies on *in vitro* and *in vivo* AD models proved that NAD treatments acted directly on mitochondrial functions and were beneficial ([**Table 1**](#T1){ref-type="table"}). In the past, the effect of a stabilized oral NAD formulation on cognitive functions in AD patients was also tested. The rationale behind this testing was based on the enhancement of the cellular bioenergetic to improve brain performance in the fight against neurodegenerative diseases. Interestingly, after 6 months of treatment, the subjects with probable AD showed no cognitive deterioration suggesting that NAD could be an excellent method to prevent the AD progression ([@B46]). However, further studies are needed to prove NAD as an effective treatment to slow down AD.

### Pioglitazone {#s4_4_3}

The **pioglitazone** is a peroxisome proliferator-activated receptor gamma (PPARγ) agonist. PPARγ is a ligand-activated nuclear transcription factor that has a role in regional transcriptional regulation of chr19q13.32 ([@B222]). This region contains the *TOMM40-APOE-APOC1* genes and, as already mentioned, *TOMM40* and *APOE4* genes are risk factors for the LOAD development. Pioglitazone was able to decrease the transcription of *TOMM40*, *APOE*, and *APOC1* genes making this molecule an interesting candidate in the AD therapy ([@B222]). In CHO cell line overexpressing APP695 isoform, pioglitazone lowered the Aβ~1-42~ level and restored the mitochondrial activity ([@B29]). These results were then confirmed *in vivo* in APP/PSEN1 mice ([**Table 1**](#T1){ref-type="table"}) ([@B30]).

Pioglitazone is usually used to treat diabetes mellitus type 2. Some years ago, the pharmaceutical company Takeda used this compound in a large and global Alzheimer's prevention study called TOMMORROW to slow down the progression from MCI to AD. The people involved were selected based on their *APOE* and *TOMM40* genotype without considering Aβ status. In 2018, phase III of this prevention trial, unfortunately, closed down because the results against symptomatic AD were negative, despite some improvement in brain metabolism.

### Dimebon {#s4_4_4}

Another compound that affects mitochondria but failed the AD clinical trial was **dimebon** (**latrepirdine**). Dimebon (latrepirdine) is an old antihistaminic drug (first generation of H1-antagonist) used against allergies that was selected in an AD clinical trial because it demonstrated cognition and memory-enhancing properties in rats treated with neurotoxin ([@B8]). Moreover, dimebon showed a substantial effect on mitochondria from different AD models ([**Table 1**](#T1){ref-type="table"}). Anyway, dimebon lacked reproducibility in the AD clinical trials and showed opposite effects on neuropsychiatric and cognitive symptoms, and daily activities ([@B8]; [@B52]). In a review from 2018, Eckert et al. asked the scientific community to reevaluate the drug dimebon as a potential treatment of AD since one of the clinical trials was able to show a slight improvement of mitochondrial functions after using dimebon in respect of the substantial effect on cognition and behavior ([@B67]).

Conclusion {#s5}
==========

In a multitude of studies, mitochondrial dysfunction has been demonstrated to be a crucial feature of AD. Several experimental results suggested that a decline of mitochondrial activity happens during aging and may get worse at early stages of the disease, contributing to disease onset. However, more thorough investigations are needed to properly address this point. The suitability of the mitochondria as a target in AD treatment is still under discussion, considering that some pharmacological trials were not successful and others were more promising, but none led to a real marketable AD drug. Nevertheless, the current understanding of AD indicates that a complete cure may not be reachable yet. Future research efforts should be invested to i) understand the real chronology of events, ii) collocate correctly the mitochondrial dysfunction inside this temporal sequence, and iii) establish if the mitochondrial dysfunctions are a primary cause or a secondary event. Only when these three key points will be correctly settled, it will be easier to intervene pharmacologically and no more time and money will be wasted for futile therapeutic studies. The failures of the respective drugs or clinical trials often happened because the underlying scientific background was not always very robust or because the models and the tools used to prove the basal hypothesis were not always well defined or validated. Therefore, a more rational approach to a complex human disease like AD is needed as well as an improvement of communication between the different scientific disciplines in order to achieve a better understanding of the disease etiology and to develop new and more effective drugs.
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